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Available online 6 March 2019Background: Thyroid hormones play a central role in cardiovascular homeostasis. Lower free triiodothyronine
(FT3) levels have been associated with worse prognosis in several conditions. However, contrary to thyrotropin
(TSH) and free thyroxine (FT4), the role of FT3 in morbidity and mortality in the general population remains
uncertain. Our objectivewas to evaluate the association betweenwithin the normal range FT3 levels andmortality
in the general population.
Methods: We evaluated 7116 adults in the National Health and Nutrition Examination Survey (NHANES)
2001–2002, 2007–2008, and 2009–2010 cycles with mortality evaluated as of December 2011. Exclusion criteria
were: pregnancy; history of thyroid disease; use of thyroid-related drugs; and TSH, FT4, or FT3 level outside the
reference range.
Results: During a median follow-up of 45 months, 357 participants died. In unadjusted analysis, lower FT3
levels were associated with higher all-cause (HR per 0.1 pg/mL increase in FT3: 0.82 [95% confidence interval,
0.78–0.87]), cardiovascular (HR 0.74 [0.66–0.83]), cancer-related (HR 0.88 [0.80–0.97]) and other cause-related
mortality (HR 0.83 [0.77–0.90]). After adjustmentwith Cox proportional hazardmodels, lower FT3 levels remained
significantly associated with higher cardiovascular mortality (HR 0.83 [0.75–0.93]), but not with all-cause (HR
0.97 [0.92–1.02]), cancer-related (HR 1.02 [0.89–1.17]), or other cause-related mortality (HR 1.00 [0.92–1.10]).
Conclusions: Lower levels of FT3 within the reference range may independently predict higher cardiovascular
mortality in the general population.






Thyroid hormones control metabolism of every tissue and play a
central role in cardiovascular homeostasis [1,2]. Both hypothyroidism
and hyperthyroidism increase risk of all-cause and cardiovascularability and freedom from bias of
rgia e Fisiologia, Unidade de
iversidade do Porto, Alameda
a).mortality [2–4], but even variations within the normal range of TSH
and free thyroxine (FT4) are associated with increased morbidity and
mortality in the general population. High-normal thyrotropin (TSH)
levels increase all-cause and cardiovascular mortality [5,6]. Conversely,
low-normal TSH levels increase risk of atrial fibrillation [7,8] and all-
cause mortality [9]. Regarding FT4, low FT4 levels have been associated
with increased all-cause mortality [5,10,11], and high FT4 levels have
been related to sudden death [12], atrial fibrillation [5,8], and athero-
sclerotic cardiovascular morbidity and mortality [13].
Lower free triiodothyronine (FT3) levels have been associated with
worse prognosis in chronic heart failure [14], acute myocardial infarc-
tion [15], cerebrovascular disease [16], chronic kidney disease [17],
116 J.S. Neves et al. / International Journal of Cardiology 285 (2019) 115–120and in critically illness [18]. However, the role of variations within the
normal range in the risk of mortality in the general population remains
uncertain.
Therefore, we aimed to evaluate the association between FT3 levels
and all-cause, cardiovascular, cancer and other cause-related mortality
in the general population.
2. Methods
2.1. Study design and participants
We analyzed data from the National Health and Nutrition Examination Survey
(NHANES). The NHANES is a nationally representative survey of the civilian noninstitu-
tionalized U.S. population conducted by the National Center for Health Statistics (NCHS)
of the Centers for Disease Control and Prevention (CDC). TheNCHSResearch Ethics Review
Board reviewed and approved the study protocol.
We included adults aged 18 years or older who participated in the continuous
NHANES survey cycles of 2001–2002, 2007–2008, and 2009–2010 in which FT4 and FT3
levels were assessed at baseline. We excluded pregnant women, participants with a prior
history of thyroid disease, participants receiving thyroid-related drugs (levothyroxine,
liothyronine, thyroid desiccated, methimazole, or propylthiouracil), and those with TSH,
FT4 or FT3 outside the reference range.
2.2. Thyroid function evaluation
InNHANESblood sampleswereprocessed, stored and shipped toCollaborative Laboratory
Services, Ottumwa, Iowa. TSH level was measured with a third generation two-site
immunoenzymatic assay, FT4 levelsweremeasured using a two-step enzyme immunoas-
say, FT3 levels were measured with a competitive binding immunoenzymatic assay.
Reference ranges in NHANES were defined as serum TSH level of 0.39–4.60 mIU/L; serum
FT4 level of 0.6–1.6 ng/dL; and serum FT3 level of 2.5–3.9 pg/mL. Antithyroperoxidase
and antithyroglobulin antibody titers were measured with two-step immunoenzymatic
assays. Detailed laboratory methods for NHANES are described elsewhere [19].
2.3. Outcomes
The main outcomes of our study were all-cause mortality, cardiovascular mortality,
cancer mortality and other cause-related mortality. Mortality status and cause of death
were determined by NHANES linked National Death Index public-access files through
December 31, 2011.
2.4. Statistical analysis
Our study population was categorized by tertiles according to FT3 levels and by
age- and sex-specific FT3 tertiles. The association of FT3 levels with all-cause mortality,
cardiovascular mortality, cancer mortality and mortality from other causes was assessed
with unadjusted, age and sex adjusted, and fully adjustedCox proportional hazardmodels.
Confounders were classified as: age (18–29 years, 30–39 years, 40–49 years, 50–59 years,
60–69 years, 70–79 years, ≥80 years); sex; race (Non-HispanicWhite, Non-Hispanic Black,
Mexican American, Other Hispanic, Other Race); body mass index (BMI; b20, 20 to b25,
25 to b30, 30 to b35, 35 to b40, ≥40 kg/m2); smoking (non-smoker, former smoker, cur-
rent smoker); education (less than 9th grade, 9–11th grade, high-school grade, some
college or associate's (AA) degree, college graduate and above); annual family incomeTable 1
Baseline characteristics of the population and according to age- and sex-specific tertiles of FT3
Total population (n = 7116) Age- a
Lower
Male sex, % 51.9
Age, years 45.0 ± 14.3
White race, % 69.5 70
Income b $25,000, % 26.8 25
Education b 9th grade, % 6.6 5
BMI, kg/m2 28.2 ± 5.5 27.4
Diabetes, % 10.5 11
Dyslipidemia, % 53.6 50
Hypertension, % 36.6 35
Chronic kidney disease, % 4.9 6
Smoking, % 19.6 17
History of CV disease, % 7.3 7
History of cancer, % 8.7 8
TSH, mIU/L 1.79 ± 0.83 1.82 ±
FT4, ng/dL 0.78 ± 0.10 0.77 ±
FT3, pg/mL 3.17 ± 0.26 2.90 ±
Abbreviations: BMI, body mass index; CV, cardiovascular.
P-values b0.05 are presented in bold.(b$25,000, $25,000 to $75,000, N$75,000); diabetes mellitus (self-reported diabetes, he-
moglobin A1c ≥ 6.5%, fasting plasma glucose level ≥126 mg/dL or use of glucose lowering
drugs); hypertension (self-reported hypertension, systolic blood pressure ≥140 mm Hg,
or diastolic blood pressure ≥90 mm Hg or use of medication to lower blood pressure);
dyslipidemia (self-reported dyslipidemia, total cholesterol ≥240 mg/dL, low-density cho-
lesterol ≥160mg/dL, high-density cholesterol b40mg/dL, triglycerides ≥200 mg/dL or use
of lipid lowering drugs); chronic kidney disease (glomerular filtration rate b60 mL/min/
1. 73 m2); previous cardiovascular disease (self-reported ischemic heart disease, heart
failure or previous stroke); self-reported history of cancer; FT4 and TSH levels. Age-
and sex-specific FT3 tertile survival was evaluated by Kaplan-Meier curves and log-rank
tests. Unadjusted and adjusted models using restricted cubic spline analyses with
three-knots were also performed to flexibly display the relationship between FT3 and
mortality. Subgroup analyses were conducted for sex, age (b65 years or ≥65 years), base-
line cardiovascular diseases and tertiles of FT4 or TSH using the likelihood ratio test for
interactions.
As complementary analyses, we performed five additional Cox proportional hazards
models. In the first model, we excluded participants with positive thyroid antibodies. In
the second model, we also included participants with FT3 between 2.0 pg/mL and the
lower limit of the reference range. In the third model, we analyzed participants with nor-
mal TSH and normal FT4, including in the analysis patients with FT3 outside the reference
range (participants with FT3 below the reference range and participants with FT3 above
the reference range). In the fourth model, we analyzed all participants without overt thy-
roid dysfunction, which was defined as high TSHwith low FT4 (overt hypothyroidism) or
low TSH and high FT4 and/or FT3 (overt hyperthyroidism). In the fifthmodel, we repeated
the main analysis excluding participants treated with amiodarone.
Continuous variables are presented as mean ± standard deviation and categorical
variables are presented as percentages. A two-sided p-value of b0.05 was considered sta-
tistically significant. Analyses were performed using Stata (version 14.2).
3. Results
3.1. Clinical characteristics
We evaluated data from 7116 participants in the NHANES. Fifty-two
percent were male and mean age was 45 ± 14 years. Higher FT3 levels
were associatedwith younger age andmale sex (Supplemental Table 1).
In the characterization according to the age- and sex-specific FT3
tertiles, subjects with higher FT3weremore likely to be non-white, cur-
rent smokers, to have a lower level of education, lower annual family
income, higher BMI, hypertension, and higher levels of FT4, compared
with those with lower FT3. They were also less likely to have CKD
(Table 1).
3.2. Free triiodothyronine levels and all-cause mortality
Lower normal FT3 levels were associated with an increase in all-
cause mortality [hazard ratio (HR) per 0.1pg/mL increase in FT3: 0.82,
95% CI 0.78–0.87, p b 0.001] in the continuous unadjusted analysis and
in the restricted cubic splines unadjusted analysis. This association
was no longer significant after adjustment for age and sex (HR 0.96,.
nd sex-specific tertiles of FT3
tertile Middle tertile Upper tertile p value
– – –
– – –
.9 70.4 66.5 0.035
.3 26.2 29.4 0.024
.0 6.8 8.5 b0.001
± 5.3 28.2 ± 5.2 29.0 ± 6.0 b0.001
.4 10.1 9.6 0.081
.2 54.7 57.0 0.003
.3 35.6 39.3 0.013
.6 4.7 2.8 b0.001
.7 20.1 21.7 0.019
.8 6.6 7.5 0.663
.3 9.3 8.5 0.746
0.82 1.78 ± 0.83 1.76 ± 0.84 0.047
0.09 0.78 ± 0.09 0.80 ± 0.11 b0.001
0.16 3.20 ± 0.13 3.49 ± 0.16 b0.001
Fig. 1. Association of FT3 with all-cause, cardiovascular, cancer, and other cause-related
mortality. Fully adjusted model: age, gender, race, BMI, smoking, education, annual
family income, diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease,
previous cardiovascular disease, history of cancer, FT4 and TSH levels. CI: confidence
interval; HR: hazard ratio.
117J.S. Neves et al. / International Journal of Cardiology 285 (2019) 115–12095% CI 0.91–1.01, p = 0.106) in the fully adjusted model (HR 0.97, 95%
CI 0.92–1.02, p = 0.221) (Fig. 1), in the analysis according to age- and
sex-specific tertiles of FT3 (Fig. 2), and in the adjusted restricted cubic
splines analysis (Supplemental Fig. 2).
3.3. Free triiodothyronine levels and cardiovascular mortality
During follow-up, 82 deaths occurred from cardiovascular disease.
In the unadjusted and adjusted models, higher FT3 levels were associ-
ated with lower cardiovascular mortality (Fig. 1). In the fully adjusted
model, the HR for cardiovascular mortality was 0.83 (95% CI 0.75–
0.93, p = 0.001) per 0.1 pg/mL increase in FT3. Comparing with partic-
ipants in the upper age- and sex-specific tertile of FT3 (Fig. 2), partici-
pants in the middle and lower tertile had higher cardiovascular
mortality [HR 1.61 (95% CI 0.91–2.84) and HR 2.41 (95% CI 1.32–4.41),
respectively; p for trend = 0.008]. The analysis of FT3 as a continuous
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Fig. 2. Kaplan-Meier curves for all-cause (A) and cardiovascbetween lower levels of FT3 and higher risk of cardiovascular mortality
both in unadjusted and in adjusted models (Supplemental Fig. 2).
3.4. Free triiodothyronine levels, cancer mortality and other cause-related
mortality
During follow-up, 98 participants died due to cancer and 177 due to
other causes. After multivariate adjustment, there was no significant
association between FT3 levels and mortality from cancer or other
causes (Fig. 1 and Supplemental Fig. 2).We also found no significant dif-
ferences in cancer and other cause-related mortality according to age-
and sex-specific FT3 tertiles (Supplemental Fig. 1).
3.5. Subgroup analyses and complementary analyses
There was no significant interaction between FT3 levels and age
groups, sex, baseline cardiovascular disease, TSH tertile, or FT4 tertile
regarding all-cause or cardiovascular mortality (Fig. 3). There were
also no significant interactions between FT3 levels and these subgroups
concerning cancer and other cause-related mortality (Supplemental
Fig. 3).
The complementary analyses presented results that were consistent
with the main analyses, either excluding the 743 patients with positive
thyroid antibodies (Supplemental Table 2), including the 115 partici-
pants with FT3 between 2.0 pg/mL and the lower limit of the reference
range for FT3 (Supplemental Table 3), including the 470 participants
with FT3 levels outside the reference range (Supplemental Table 4),
including the 832 participants without overt thyroid dysfunction
(Supplemental Table 5), or excluding the 63 participants who were
treated with amiodarone (Supplemental Table 6).
4. Discussion
Our study showed an inverse association between FT3 levels
within the reference range and cardiovascular mortality. The inverse
association of FT3 with cardiovascular mortality remained statistically
significant after adjustment for demographic variables, relevant comor-
bidities, FT4 and TSH levels. No interactions regarding cardiovascular
mortalitywere found between FT3 and age, sex, baseline cardiovascular
disease and tertiles of FT4 or TSH. Consequently, our study suggests that
a lower FT3 level, even within the reference range, is an independent
predictor of higher cardiovascular mortality.
Most studies that have evaluated the effects of thyroid hor-
mones levels within the reference range on mortality have focused
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ular mortality (B) by age- and sex-specific FT3 tertiles.
Fig. 3. Subgroup analysis of the association between FT3 levels, all-cause mortality, and cardiovascular mortality. Analysis adjusted for age, sex, race, BMI, smoking, education, annual
family income, diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, previous cardiovascular disease, history of cancer, FT4 and TSH levels. HR: hazard ratio.
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[14–16], to our knowledge this is the first study showing an associa-
tion between lower levels of FT3 and higher cardiovascular mortality
in the general population. In a prospective cohort study of ambulatory
patients with chronic heart failure, not only low T3 levels, but also T3
evaluated as a continuous variable was associated with a composite
end point of adverse cardiovascular outcomes (ventricular assist de-
vice placement, heart transplantation, or death) [20]. Among patients
hospitalized with previous cardiovascular disease, Pfister et al. [21]
also shown that lower FT3 levels within the reference range were asso-
ciated with higher mortality. Meuwese et al. [22], also showed in
patients with chronic kidney disease in maintenance hemodialysisthat relatively lower basal triiodothyronine concentrations were asso-
ciated with higher mortality comparing with patients with higher
levels.
Several studies have previously assessed the association of FT3 levels
with all-cause mortality among elderly patients. In the Milan Geriatrics
75+ Cohort Study, lower FT3 was associated with increased all-cause
mortality among older outpatients with normal TSH [23]. Also, in
the Leiden 85-Plus Study, including 599 participants followed from
85 years through 89 years of age, lower FT3 was associated with all-
cause mortality [24]. In the Chianti Area Study, including 951 subjects
with 65 years or more, there was also a trend for participants with
lower FT3 levels to present higher all-cause mortality [25].
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the Chianti Area Study [25] or in the Kangbuk Samsung Health Study
including Korean healthy participants, with a mean age of 40 years
and only 5% above 60 years of age [10]. Differences among the popula-
tions studied, particularly regarding age, probably explain much of the
heterogeneity in the results found across studies.
Multiple pathways have been implicated in cardiovascular protec-
tion by thyroid hormones [2]. Triiodothyronine modulates lipid profile,
endothelial function, blood pressure, and directly improves cardiac
function [2]. Thyroid hormones have also been proposed to be
cardioprotective through modulation of mitochondrial function and
reduction of cardiomyocytes apoptosis [26,27]. Triiodothyronine is the
biologically active thyroid hormone and therefore an association be-
tween free triiodothyronine levels and cardiovascular mortality is not
surprising. However, it is also possible that lower FT3 levels may only
constitute a marker rather than a direct mediator of increased cardio-
vascular risk. Low triiodothyronine levels are commonly found in
patients with acute critical illness and severe chronic diseases [28].
The occurrence of low triiodothyronine syndrome, one of themost com-
mon forms of non-thyroidal illness syndrome (alterations in thyroid
hormones without any underlying intrinsic thyroid disorder), can be
explained by changes in deiodinase activity, thyroid hormone binding,
peripheral metabolism, or changes in the hypothalamic-pituitary-
thyroid axis [28]. The severity of disease has been correlated with the
decrease of thyroid hormone levels. Whether these changes are detri-
mental or adaptive during acute or chronic disease remains controversial.
In a recent meta-analysis of studies including patients with cardiovascu-
lar disease, low triiodothyronine syndrome was independently associ-
ated with increased all-cause and cardiovascular mortality [29]. Our
study reinforces results from this meta-analysis regarding cardiovascular
mortality but not all-cause mortality in the general population.
We analyzed data from the NHANES which includes a large num-
ber of participants and is designed to be representative of the non-
institutionalized US population, spanning a wide age distribution.
The availability of comprehensive information about the participants
allowed for adjustment for themain biologically plausible confounders.
Our results were consistent across main and complementary analyses.
Nevertheless, we must highlight that thyroid function was only
evaluated at baseline. We cannot exclude that the associations with
mortality would differ if FT3 was also evaluated during follow-up. Fur-
thermore, in NHANES the evaluation of reverse triiodothyronine levels
was not performed. It is possible that the effects of FT3 in mortality dif-
fer according to the levels of reverse triiodothyronine. We must also
highlight that previous cardiovascular disease was self-reported by the
participants. We cannot exclude the presence of bias on the classifica-
tion of baseline cardiovascular disease. Moreover, as all observational
studies, our analysis must be interpreted as exploratory. It is possible
that residual confounding exists due to unmeasured variables.
Our results suggest that FT3 levels may contribute to the stratifica-
tion of cardiovascular risk in the general population. Even after adjust-
ment for TSH, FT4, and traditional cardiovascular risk factors, lower
FT3 levels within the reference range independently predicted cardio-
vascular mortality. If these findings are confirmed in other cohorts,
the evaluation of FT3 levels might be included in cardiovascular risk
scores allowing a finer hierarchization of the patient's cardiovascular
risk profile.
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